AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Summary

This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein.

Timeline

Start

2010-03

Primary completion

2012-03

Completion

2012-03

Drugs

Indications